Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Yield10 Bioscience, Inc. (YTEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.66-0.14 (-2.41%)
At close: 4:00PM EDT
5.90 +0.24 (+4.24%)
After hours: 04:18PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close5.80
Open5.77
Bid5.35 x 800
Ask5.90 x 1200
Day's Range5.66 - 5.78
52 Week Range5.20 - 23.49
Volume9,242
Avg. Volume41,885
Market Cap27.572M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for YTEN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Yield10 Bioscience, Inc.
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
Advertisement
Advertisement